Previous evidence has suggested a relationship between male self-reported body size and the risk of developing prostate cancer. In this UK-wide case-control study, we have explored the possible association of prostate cancer risk with male self-reported body size. We also investigated body shape as a surrogate marker for fat deposition around the body. As obesity and excessive adiposity have been linked with increased risk for developing a number of different cancers, further investigation of self-reported body size and shape and their potential relationship with prostate cancer was considered to be appropriate.
The study objective was to investigate whether underlying associations exist between prostate cancer risk and male self-reported body size and shape.
Data were collected from a large case-control study of men (1928 cases and 2043 controls) using self-administered questionnaires. Data from self-reported pictograms of perceived body size relating to three decades of life (20’s, 30’s and 40’s) were recorded and analysed, including the pattern of change. The associations of self-identified body shape with prostate cancer risk were also explored.
Self-reported body size for men in their 20’s, 30’s and 40’s did not appear to be associated with prostate cancer risk. More than half of the subjects reported an increase in self-reported body size throughout these three decades of life. Furthermore, no association was observed between self-reported body size changes and prostate cancer risk. Using ‘symmetrical’ body shape as a reference group, subjects with an ‘apple’ shape showed a significant 27% reduction in risk (Odds ratio = 0.73, 95% C.I. 0.57–0.92).
Change in self-reported body size throughout early to mid-adulthood in males is not a significant risk factor for the development of prostate cancer. Body shape indicative of body fat distribution suggested that an ‘apple’ body shape was protective and inversely associated with prostate cancer risk when compared with ‘symmetrical’ shape. Further studies which investigate prostate cancer risk and possible relationships with genetic factors known to influence body shape may shed further light on any underlying associations.
Citation: Aladwani M, Lophatananon A, Robinson F, Rahman A, Ollier W, Kote-Jarai Z, et al. (2020) Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study. PLoS ONE 15(9): e0238928. https://doi.org/10.1371/journal.pone.0238928
Editor: Sabine Rohrmann, University of Zurich, SWITZERLAND
Received: April 7, 2020; Accepted: August 26, 2020; Published: September 17, 2020
Copyright: © 2020 Aladwani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The PRACTICAL consortium has defined policies and legal restrictions on sharing the data publicly, due to the consent process under which the data was collected. However, data are available upon request from The Institute of Cancer Research and The University of Manchester for researchers who meet the criteria for access to confidential data. Access requests may be sent to PRACTICAL@icr.ac.uk.
Funding: This research was supported by the Prostate Cancer Research Foundation (currently Prostate Action) and Cancer Research UK Grant C5047/A8385. We acknowledge support from the NIHR to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. KM and AL are supported by the NIHR Manchester Biomedical Research Centre and by the ICEP ("This work was also supported by CRUK [grant number C18281/A19169]). MA is supported by Kuwait’s Ministry of Health. The funder provided support in the form of salaries for authors [RE, KM, AL, MA], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” The British Association of Urological Surgeons’ Section of Oncology only played a role in notification of prostate cancer cases and there is no other additional roles.
Competing interests: We can confirm that The British Association of Urological Surgeons’ Section of Oncology as commercial affiliation does not alter adherence to PLOS ONE policies on sharing data and materials.
Prostate cancer is the most prevalent cancer in men . It is also the third most common cancer-specific cause of death for men living in Europe [2, 3]. In 2016, it accounted for approximately one quarter of all cancers diagnosed in men within the UK . Apart from the established cancer risk factors, such as age, ethnicity and family history of prostate cancer in first degree-relatives, other potential risk factors include height, obesity/high body mass index (BMI) and levels of insulin-like growth factor-I [5–7].
Over the last few decades, obesity has increased by approximately 30% in European men [8, 9]. This has been linked to increased risk for developing several chronic diseases and cancers . Extensive studies have investigated the association of both obesity and body size with prostate cancer risk. However, this relationship remains inconclusive [11–15]. Anthropometrics that have been used to measure obesity and body adiposity include waist circumference, waist-hip ratio and BMI . The majority of epidemiologic studies investigating prostate cancer risk have used BMI to evaluate obesity rather than body fat distribution . Previous studies have suggested that high BMI is associated with increased risks for advanced, aggressive and fatal prostate cancer [13, 15, 17–22]. In contrast, other studies have observed a decreased risk of localised/indolent cancer [13, 15, 23–25]. A large meta-analysis consisting of 27 prospective studies of prostate cancer observed no or weak association between BMI and total prostate cancer . Similar findings have come from another systematic review examining the exposure in early adult life . These conflicting results may in part be due to the fact that BMI has been criticised for its inaccuracy in measuring obesity and its ability to differentiate adipose and non-adipose tissues [28, 29]. This suggests that any association could be dependent on particular disease subtypes and the age of exposure [6, 12, 13, 30].
Both body shape and body size have often been used to describe the characteristics of the human body in health-related research. Defining obesity or adiposity through the use of clinical judgement including a consideration of body size appearance provides an alternative approach for determining the wider distribution of fat tissue over time.
The issue of whether weight change during adulthood is more strongly associated with prostate cancer than cross-sectional ‘current’ adiposity has not as yet been fully explored [31, 32]. Prostate cancer is characterised as being a slow developing disease. Thus the age that obesity develops in early adult life may be an important factor within the aetiology of this cancer [27, 33–35]. Moreover, early changes in prostate tissue have been seen in men during their early adulthood, suggesting that body size over lifetime is important [33, 36]. Adult weight change is a dynamic measure that could reflect imbalances in weight over time and it is thought to be more accurate than a static measure of adiposity such as BMI [19, 37]. However, these studies have reported inconsistent results [19, 31, 32]. Some studies found positive associations between weight gain and prostate cancer  whereas others have found an inverse association  or no association at all [14, 21]. In this study we specifically address the issues of whether male self-reported body size and overall body shape and self-reported body size and its change across three decades of life are associated with prostate cancer risk.
The ‘Prostate Cancer Study on Gene-Environment Interactions’ is a large scale case-control study identifying and investigating potential risk factors for the development of prostate cancer in the UK. The study used a self-administered questionnaire and written informed consent was obtained from each participant. Cases comprised adult men >36 years at diagnosis with histologically confirmed prostate cancer. Male adult controls were selected from the same general practices as cases. Eligible controls were men without history of prostate cancer and were within an age range of ±5 years of cases. This study received ethical committee approval MREC/99/4/013 (Trent Research Ethics Committee), 07/MRE04/29 (Nottinghamshire County Teaching and Primary Care Trust).
Epidemiological data were collected for two time periods; the first between 1997–2004 and the second between 2007–2009. In the second period, some additional questions were added and other questions expanded within the questionnaire to provide more in-depth information, including information on body shape. This was done following a preliminary analysis of data collected from the first period. Data collection from the two time periods involved different subjects and no repeated measurements were performed. Individuals did not contribute their data more than once.
Data on education was based on the UK educational system and social class was based on the UK occupational social class classification. Data on self-reported body size were available from both periods, but data on body shape were only available from the second period of data collection. Self-reported body size at different ages was assessed using a pictogram (Fig 1) with drawings of body silhouettes of nine different sizes ranging from 1 (very thin) to 9 (severely obese) . Subjects were asked to recall information relating to their self-reported body size during their 20’s, 30’s and 40’s. Cases and controls were asked to rate their perceived body size for the last 5 year period prior to diagnosis in case group and for the last 5 years prior to receiving the questionnaire in control group. Participants were excluded from the analysis if there were incomplete data (i.e. missing data for any decade). This was done to ensure each participant has data to investigate self-reported body size changes throughout decades. 1928 cases and 2043 controls were available for the analysis of self-reported body size in the 20’s and 30’s. Six subjects were younger than 40 years of age at the time data were collected; hence the number of cases and controls eligible for self-reported body size analysis in the 40’s were 1924 and 2041 respectively. Ordinal scale data (scale of 1 to 9) for self-reported body size at age 20’s, 30’s, 40’s were grouped into ‘thin’ (scale 1–3), ‘medium’ (scale 4–6) and ‘large’ (scale 7–9).
To explore the effect of self-reported body size increase during adulthood on prostate cancer risk, we restricted our analysis to include only subjects whose self-reported body size remained as medium size from 20’s to 40’s as our reference group and subjects whose self-reported body size was medium both in their 20s and 30s but increased to large in their 40’s as our exposed group (Fig 1). There are 1057 cases and 1099 controls.
For body shape, participants were asked to select their body shape in four different forms (apple, pear, oval and symmetrical) that best represented their body shape throughout their life. Description of each body shape type was provided to aid subject’s understanding on its meaning (‘Apple’ shape is where body fat is distributed mainly around the central abdominal area; ‘Pear’ shape is where body fat is distributed mainly around the hip and thigh; ‘Oval’ shape is where body fat is distributed around the neck, chest, abdominal area and thigh; ‘Symmetrical’ shape is where the person has lean body with no fat). The numbers of subjects included in this particular analysis were 1329 cases and 812 controls.
Logistic regression analysis was performed on the data using Stata version 15.0 . Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for total prostate cancer risk. Forward stepwise logistic regression was performed on demographic factors to identify potential confounders. The final multivariate logistic regression model included education, ethnicity, study phase (I and II) and family history of prostate cancer in first-degree relatives. Multivariable logistic regression was fitted with all confounders. Age was also included as an a-priori variable in all regression models. For self-reported body size, medium size was used as reference category and for pattern of change, no change from 20s to 40s was used as reference group. In the multivariate model, self-reported body size at age 30’s and 40’s were adjusted further to self-reported body size at age 20’s to minimise the effect of correlation between self-reported body size at age 20’s to age 30’s and 40’s. For body shape, symmetrical shape was used as reference category. Estimated risks were obtained from multivariate logistic regression models. A significant odds ratio is considered when 95% C.I does not include 1.
We collected data on current BMI from both periods. A sensitivity analysis was performed to explore if self-reported body size can be used as a proxy marker for BMI. We used the self-reported body size and BMI reported during the last 5 years prior to completing the questionnaire only in the controls due to the fact that prostate cancer may have affected current BMI in cases. Data were available in 766 controls. BMI as a continuous variable was normally distributed hence we applied Analysis of Variance (ANOVA) to explore the differences among group means. A finding was deemed to be statistically significant when the P-value was less than 0.05.
As they are no previous studies on body shape and prostate cancer, we computed our study power based on exposure in our study. Our study of 1329 case and 812 controls with a probability of exposure (apple body shape) among controls of 0.62, had a 95% study power to detect odds ratios for disease of 0.72 or 1.41 .
The overall study response rates after initial consent to complete the questionnaire were 85.0% for cases and 74.4% for controls. Table 1 shows the study population characteristics. The median age for both case and control subjects was 60 and 59 years respectively. The vast majority of study subjects described themselves as white (98%).
Table 2 summarises the number of subjects and their self-reported body size at each of the three decades of their life. The majority of participants was medium across all three decades in both case and control groups.
Table 3 summarises odds ratios of self-reported body size changes and prostate cancer risk. Both cases and controls have similar percentage of self-reported body size change from medium to large in their 40’s (~30%). The result suggests that there is no association with cancer risk for subjects whose self-reported body size increased from medium to large as compared to subjects with medium self-reported body size throughout their adulthood.
Table 4 presents estimated risks of different self-reported body shape and prostate cancer risk. Compared to symmetrical shape, subjects with an apple shape were at 27% risk reduction (OR in the fully adjusted model = 0.73 with 95% CI 0.57–0.92). Both pear and oval shape did not show any association with prostate cancer risk in the fully adjusted model of 1.44 (95% CI 0.77–2.69) and 0.82 (95% CI 0.59–1.13) respectively. Although, the association is not significant, but the direction of effect suggested that adipose tissue distributed around the hip and thigh (pear) is at higher risk, while abdominal fat distribution (apple, and oval) is at lower risk.
Results from sensitivity analysis (only in the control group) using ANOVA test is presented in Table 5. The significant p-value suggested that mean BMI in each group is a statistically significant difference. BMI increases with increased self-reported body size indicative of a good proxy between BMI and body size.
Three key areas potentially relating to increased risk for prostate cancer were explored in this study; self-reported body size at early and mid-adulthood, self-reported body size changes over decades in life, and self-identified body shape.
Self-reported body size (thin, medium, and large) ranging across three decades (20’s, 30’s and 40’s) was explored and analysis suggested no associations between the self-reported body size at each stage of life among cases and control group and risk of prostate cancer however our analysis could be underpowered given the relatively small numbers in the 20’s/large and 40’s/thin category. Furthermore, the analysis suggested that 55% of both case and control subjects had a history of changes in self-reported body size. Our ad hoc analysis also showed that the magnitude of changes of self-reported body size from age 20’s to 40’s varies between individuals (result not shown here). Approximately 53% of those self-reported body size changes were of increase in size (either for both periods-20s to 30s and 30s to 40s or at 20s to 30s and no change in 30s to 40s). The possible explanation for increase in body size is because of decreased metabolic rate with ageing and accumulation over the years of unburned calorie intakes. Environmental factors such as eating high-fat foods or lack of exercise, as well as Sedentary Lifestyle Syndrome (SeDS) could also be accountable for increasing in body size . These possible explanations are compatible with the considerable social and life style changes that have occurred across the UK over the last 30 years.
The findings of previous studies regarding obesity at early and mid-adulthood are inconclusive. Our results are consistent with the majority of epidemiologic studies that found no associations between self-reported body size in early as well as middle to late adulthood and prostate cancer risk [14, 21, 27, 39, 44, 45]. More recently, a research group (the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium) investigated potential causal relationship between BMI and prostate cancer using genetic approaches to analyse 20848 cases and 20214 controls. This also failed to identify any significant associations between BMI and prostate cancer . Our study also did not find any association between changes in self-reported body size over decades (increase in self-reported body size to large in the 40’s compared to remains medium throughout) and prostate cancer risk. This finding is inconsistent with several other studies where some relationships with prostate cancer were observed [14, 19, 24, 38, 47, 48]. This inconsistency could be due to the different measurements used by these studies which used actual weight, BMI or waist circumference to indicate the change in body size. In contrast, in our study we used pictograms as a surrogate for body size. We also performed analyses of BMI and perceived body size within different social class and education in the control group and the results suggested a very similar correlation to that seen in the main sensitivity analysis. Furthermore, the other studies used multiple parameters to measure body size when investigating the relationship of change of body size with prostate cancer. As such there was therefore a higher possibility of obtaining statistical significant findings in at least one of the measurement parameters. The other limitation is that our data is only limited to middle age (40s) hence this may not be the period in life that obesity associates with prostate cancer. Our results which failed to show association are in keeping with the majority of other studies that investigated the association between weight change and prostate cancer risk [12, 31, 32, 39, 44, 45, 49–53].
A limitation of using pictorial illustration is its inability to make an actual measurement of changes in body size in comparison with using other parameters such as weight, waist circumference or waist-hip ratio, BMI or body fat mass. As such, pictorial assessment of self-reported body size is relative, but it may be better for showing body size change over long time windows. Pictograms are considered to be a valid and useful method to assess self-reported body size and differentiate thin and obese individuals . The Stunkard Figure Rating (SFR) scale of body size  tool has been validated for historic recall of body size and was used in a large European population to explore correlation between self-reported body silhouettes and the previously measured (9–23 years) BMI . The authors reported an area under the curve of 0.92 (95% CI 0.87, 0.97) in women and 0.85 (95% CI 0.75, 0.95) in men for identifying obesity at age 30 using body silhouettes vs previously measured BMI at age 30 (±2y). The findings were also similar for previously self-reported BMI, 0.92 (95% CI 0.88, 0.95) and 0.90 (95% CI 0.85, 0.96) in women and men respectively. Another study assessing adolescent body size found that Stunkard’s method was a useful indicator in absence of measured BMI . It is also has been reported that recalled body size using pictograms showed a strong correlation with measured weight at age 20–40 years with a correlation ranging from 0.51 to 0.95 [57–59]. Our result from sensitivity analysis in controls suggested that pictogram can potentially be used for recall of body size. Nevertheless, personal perception of body size of each individual could introduce bias such as classification bias.
Cohort studies often obtain more valuable data by longitudinally measuring and recording body weight, waist/hip circumference and body fat mass. Implementing this approach was not possible in our study. Some medical conditions, such as hypo or hyperthyroidism, can affect body size. However the prevalence of both these conditions in the UK is low (1–2% for both conditions)  and therefore unlikely to affect our results. As our study is subject to classification bias, we opted to broadly group body size into three groups to minimise any bias; i.e. thin, medium and large.
We are not aware of any published research on the prevalence of different types of body fat distribution in the population. However waist and chest circumference measurement in males are the closest for describing whether a person shape can be described as ‘apple’ or be a proxy of central adiposity . Male shape seems to remain highly stable throughout adult life, therefore it is reasonable to assume that characteristic of body fat distribution also remains the same.
Our results suggest that subjects with an ‘apple’ shape indicative of body fat distributed mainly around the abdomen, were at reduced risk with both adjusted and unadjusted when compared to those with a ‘symmetrical’ shape. However, the ‘pear’ and ‘oval’ body shapes did not show any statistically significant associations. A recent cohort study reported by Barberio involving 26607 subjects, found central body adiposity to be more associated with cancer risk than overall body size . Although the cohort examined the association with cancer in general, our results of self-identify body shape indicative of the distribution of fat tissue around the body suggested similar findings.
In contrast to ‘apple’ or ‘pear’ body shape, hip circumference indicates increased amounts of subcutaneous fat. Thus ‘apple’ body shape in actual measurement would predict wider waist circumference (WC) or higher waist to hip ratio (WHR). Studies using actual measurement have shown increased risk in advanced or high-grade prostate cancer in such individuals [3, 16, 30, 63, 64].
Several possible explanations have been proposed regarding association between central adiposity and prostate cancer. Adiposity can potentially impact through multiple hormonal pathways. Adiposity has been associated with higher levels of insulin, insulin like growth factor I, leptin, and inflammatory cytokines. It has also been linked with lower levels of adiponectin and free testosterone. All of these may impact on prostate cancer development and progression [20, 65–72]. Moreover, some studies showed that adiposity lowered the risk of non-aggressive prostate cancer while at the same time increased the risk for aggressive and high-grade prostate cancer [3, 5, 8, 14, 16, 20, 21, 24, 25, 30, 33, 73]. However other studies have observed weak or no association with prostate cancer and disease subtypes [12, 74–76].
As yet no other study reported in the literature has used body shape as proxy measure of body fat distribution to investigate possible associations with prostate cancer. Our findings suggest that abdominal fat deposition (apple body shape) maybe protective of prostate cancer.
Diabetes is known to be linked with obesity and also shows an inverse association with the risk of prostate cancer [77–79]. One of the limitations is that we collected data on diabetes only in period 2 with no details of diabetes type. However, we carried out logistic regression analysis incorporating diabetes in our model, our results remain the same. Likewise, we also investigated the association of both smoking and physical activity with prostate cancer and there were no associations. Therefore, we did not include these variables in our final model.
In this study, we used self-reported descriptions within the questionnaire to capture the types of body fat distribution. This approach is likely to be less accurate than using 3-dimensional body shape scanning as used in UK National Sizing survey  conducted in 2001 to 2002. This cross-sectional study of 9617 adults found that male body shape remained highly stable throughout adulthood. Such quantitative approaches may reveal further insights into the role and influence of lipidosity and its site of deposition on prostate cancer risk and development.
We thank The UK Genetic Prostate Cancer Study Collaborators (List of collaborators can be found at: https://d1ijoxngr27nfi.cloudfront.net/docs/default-source/default-document-library/collaborators_may_18-_surname.pdf) and the British Association of Urological Surgeons’ Section of Oncology for their collaboration on the study. We would also like to thank all men who participated in the study.
- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424.
- 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010;127:2893–917. pmid:21351269.
- 3. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiology Biomarkers and Prevention. 2008;17:3252–61. pmid:16818856.
- 4. Andy K, John B. Cancer registration statistics, England: 2016 2018. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/final2016.
- 5. Stocks T, Hergens M-P, Englund A, Ye W, Stattin P. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. International Journal of Cancer. 2010;127:1660–8. pmid:20087861
- 6. Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. European Urology. 2013;63:800–9. pmid:23219374
- 7. Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, Patterson L, Dubin JA, Mourtzakis M. Elevated C-Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer. Prostate. 2017;77:211–21. pmid:27699825.
- 8. De Nunzio C, Albisinni S, Freedland SJ, Miano L, Cindolo L, Finazzi Agrò E, et al. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter italian cohort study. Urologic Oncology: Seminars and Original Investigations. 2013;31:997–1002. pmid:21925906.
- 9. Berghöfer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200. pmid:18533989
- 10. Markozannes G, Tzoulaki I, Karli D, Evangelou E, Ntzani E, Gunter MJ, et al. Diet, body size, physical activity and risk of prostate cancer: An umbrella review of the evidence. European Journal of Cancer. 2016;69:61–9. pmid:27816833.
- 11. Stevens VL, Jacobs EJ, Maliniak ML, Patel AV, Gapstur SM. No association of waist circumference and prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology Biomarkers and Prevention. 2017;26:1812–4. pmid:24585409.
- 12. Möller E, Adami HO, Mucci LA, Lundholm C, Bellocco R, Johansson JE, et al. Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes and Control. 2013;24:2143–55. pmid:24048969.
- 13. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Annals of Oncology. 2012;23:1665–71. pmid:22228452.
- 14. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109:675–84. pmid:17211863.
- 15. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Cancer Causes and Control. 2006;17:989–1003. pmid:16933050.
- 16. Boehm K, Sun M, Larcher A, Blanc-Lapierre A, Schiffmann J, Graefen M, et al. Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: Results from the North-American case-control study Prostate Cancer & Environment Study. Urologic Oncology: Seminars and Original Investigations. 2015;33:494.e1-.e7. pmid:26278366.
- 17. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: A systematic review and meta-analysis. Cancer Prevention Research. 2011;4:486–501. pmid:21233290.
- 18. Zhong S, Yan X, Wu Y, Zhang X, Chen L, Tang J, et al. Body mass index and mortality in prostate cancer patients: a dose–response meta-analysis. Prostate Cancer and Prostatic Diseases. 2016;19:122–31. pmid:26754262
- 19. Chen Q, Chen T, Shi W, Zhang T, Zhang W, Jin Z, et al. Adult weight gain and risk of prostate cancer: A dose-response meta-analysis of observational studies. International Journal of Cancer. 2016;138:866–74. pmid:26356247.
- 20. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15:1977–83. pmid:17035408.
- 21. Littman AJ, White E, Kristal AR. Anthropometrics and Prostate Cancer Risk. American Journal of Epidemiology. 2007;165:1271–9. pmid:17395597
- 22. Perez-Cornago A, Appleby PN, Pischon T, Tsilidis KK, Tjonneland A, Olsen A, et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC medicine. 2017;15(1):115. Epub 2017/07/14. pmid:28701188; PubMed Central PMCID: PMC5508687.
- 23. Freedland SJ, Giovannucci E, Platz EA. Are Findings from Studies of Obesity and Prostate Cancer Really in Conflict? Cancer Causes & Control. 2006;17:5–9. pmid:16411047
- 24. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al. Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology and Prevention Biomarkers. 2007;16:63–9. pmid:17179486.
- 25. Hsing AW, Sakoda LC, Chua SC. Obesity, metabolic syndrome, and prostate cancer. The American Journal of Clinical Nutrition. 2007;86:843S–57S. pmid:18265478
- 26. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet. 2008;371:569–78.
- 27. Robinson WR, Poole C, Godley PA. Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes and Control. 2008;19:793–803. pmid:18347923.
- 28. Nomura AM. Body size and prostate cancer. Epidemiologic Reviews. 2001;23:126–31. pmid:11588836.
- 29. Chan JM, Stampfer MJ, Giovannucci EL. What causes prostate cancer? A brief summary of the epidemiology. Seminars in Cancer Biology. 1998;8:263–73. pmid:9870033
- 30. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. British Journal of Cancer. 2009;100:1799–805. pmid:19436298.
- 31. Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, et al. Weight change and prostate cancer incidence and mortality. International Journal of Cancer. 2012;131:1711–9. pmid:22213024.
- 32. Chamberlain C, Romundstad P, Vatten L, Gunnell D, Martin RM. The association of weight gain during adulthood with prostate cancer incidence and survival: A population-based cohort. International Journal of Cancer. 2011;129:1199–206. pmid:21064096.
- 33. Möller E, Wilson KM, Batista JL, Mucci LA, Bälter K, Giovannucci E. Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. International Journal of Cancer. 2016;138:853–65. pmid:26355806.
- 34. Sutcliffe S, Colditz GA. Prostate cancer: is it time to expand the research focus to early-life exposures? Nature Reviews Cancer. 2013;13:208–518. pmid:23363989
- 35. Robinson WR, Stevens J, Gammon MD, John EM. Obesity before Age 30 Years and Risk of Advanced Prostate Cancer. American Journal of Epidemiology. 2005;161:1107–14. pmid:15937019
- 36. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The Frequency of Carcinoma and Intraepithelial Neoplasia of the Prostate in Young Male Patients. The Journal of Urology. 1993;150:379–85. pmid:8326560
- 37. Ballard-Barbash R, Schatzkin A, Taylor PR, Kahle LL. Association of change in body mass with breast cancer. Cancer research. 1990;50:2152–5. pmid:2317807.
- 38. Hernandez BY, Park SY, Wilkens LR, Henderson BE, Kolonel LN. Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort. Cancer Epidemiology Biomarkers and Prevention. 2009;18:2413–21. pmid:19723920.
- 39. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in Relation to Prostate Cancer Risk in the Netherlands Cohort Study. American Journal of Epidemiology. 2000;151:541–9. pmid:10733035
- 40. Stunkard AJ, Sørensen T, Schulsinger F. Use of the Danish Adoption Register for the study of obesity and thinness. Research publications—Association for Research in Nervous and Mental Disease. 1983;60:115–20. pmid:6823524.
- 41. StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 2017.
- 42. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Controlled clinical trials. 1990;11(2):116–28. Epub 1990/04/01. pmid:2161310.
- 43. Wellman NS, Friedberg B. Causes and consequences of adult obesity: health, social and economic impacts in the United States. Asia Pacific Journal of Clinical Nutrition. 2002;11(s8):S705–S9.
- 44. Discacciati A, Orsini N, Andersson S-O, Andrén O, Johansson J-E, Wolk A. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. British Journal of Cancer. 2011;105:1061–8. pmid:21847119
- 45. Giles GG, Severi G, English DR, McCredie MRE, MacInnis R, Boyle P, et al. Early growth, adult body size and prostate cancer risk. International Journal of Cancer. 2003;103:241–5. pmid:12455039.
- 46. Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, et al. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes and Control. 2015;26:1603–16. pmid:26387087.
- 47. Mori M, Masumori N, Fukuta F, Nagata Y, Sonoda T, Miyanaga N, et al. Weight gain and family history of prostate or breast cancers as risk factors for prostate cancer: results of a case-control study in Japan. Asian Pacific journal of cancer prevention: APJCP. 2011;12:743–7. pmid:21627376.
- 48. Rapp K, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, et al. Weight change and cancer risk in a cohort of more than 65 000 adults in Austria. Annals of Oncology. 2007;19:641–8. pmid:18056917
- 49. Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG. Case-control study of anthropometric measures and prostate cancer risk. International Journal of Cancer. 2004;110:278–83. pmid:15069694
- 50. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1997;6:557–63. pmid:9264267.
- 51. Jonsson F, Wolk A, Pedersen NL, Lichtenstein P, Terry P, Ahlbom A, et al. Obesity and hormone-dependent tumors: Cohort and co-twin control studies based on the Swedish Twin Registry. International Journal of Cancer. 2003;106:594–9. pmid:12845658
- 52. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, et al. Lifestyle and Anthropometric Risk Factors for Prostate Cancer in a Cohort of Iowa Men. Annals of Epidemiology. 2000;10:361–9. pmid:10964002
- 53. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult Weight Gain and Adiposity-Related Cancers: A Dose-Response Meta-Analysis of Prospective Observational Studies. JNCI: Journal of the National Cancer Institute. 2015;107. pmid:25757865
- 54. Bulik C, Wade T, Heath A, Martin N, Stunkard A, Eaves L. Relating body mass index to figural stimuli: population-based normative data for Caucasians. International Journal of Obesity. 2001;25:1517–24. pmid:11673775
- 55. Lonnebotn M, Svanes C, Igland J, Franklin KA, Accordini S, Benediktsdottir B, et al. Body silhouettes as a tool to reflect obesity in the past. PloS one. 2018;13(4):e0195697. Epub 2018/04/26. pmid:29694359; PubMed Central PMCID: PMC5918897.
- 56. Lo W-S, Ho S-Y, Mak K-K, Lam T-H. The Use of Stunkard’s Figure Rating Scale to Identify Underweight and Overweight in Chinese Adolescents. PloS one. 2012;7:e50017. pmid:23189177
- 57. Bayomi DJ, Tate RB. Ability and Accuracy of Long-term Weight Recall by Elderly Males: The Manitoba Follow-up Study. Annals of Epidemiology. 2008;18:36–42. pmid:17855121
- 58. Must A, Willett WC, Dietz WH. Remote Recall of Childhood Height, Weight, and Body Build by Elderly Subjects. American Journal of Epidemiology. 1993;138:56–64. pmid:8333427
- 59. Casey VA, Dwyer JT, Berkey CS, Coleman KA, Gardner J, Valadian I. Long-term memory of body weight and past weight satisfaction: a longitudinal follow-up study. The American Journal of Clinical Nutrition. 1991;53:1493–8. pmid:2035478
- 60. Gilbert J. Hypothyroidism. Medicine (United Kingdom). 2017;45:506–9.
- 61. Wells JC, Treleaven P, Cole TJ. BMI compared with 3-dimensional body shape: the UK National Sizing Survey. The American Journal of Clinical Nutrition. 2007;85:419–25. pmid:17284738
- 62. Barberio AM, Alareeki A, Viner B, Pader J, Vena JE, Arora P, et al. Central body fatness is a stronger predictor of cancer risk than overall body size. Nature Communications. 2019;10:383. pmid:30670692
- 63. Jackson MD, Walker SP, Simpson CM, McFarlane-Anderson N, Bennett FI, Coard KCM, et al. Body size and risk of prostate cancer in Jamaican men. Cancer Causes & Control. 2010;21:909–17. pmid:20157773
- 64. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and prostate cancer risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2003;12:1417–21. pmid:14693731.
- 65. Wilson KM, Giovannucci EL, Mucci LA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian journal of andrology. 2012;14:365–74. pmid:22504869.
- 66. Stattin P, Söderberg S, Hallmans G, Bylund A, Kaaks R, Stenman U-H, et al. Leptin Is Associated with Increased Prostate Cancer Risk: A Nested Case-Referent Study 1. The Journal of Clinical Endocrinology & Metabolism. 2001;86:1341–5. pmid:11238530
- 67. Gade-Andavolu R, Cone LA, Shu S, Aa Morrow, editors. Molecular Interactions of Leptin and Prostate Cancer. Cancer J; 2006.
- 68. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology. 2005;65:1168–72. pmid:15922427
- 69. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al. The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. European Urology. 2011;60:106–17. pmid:21497433
- 70. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. The Journal of Urology. 2005;174:1266–70. pmid:16145390
- 71. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen Y-C, Stampfer MJ, et al. Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era. Cancer Epidemiology Biomarkers & Prevention. 2005;14:1262–9. pmid:15894683.
- 72. Roberts DL, Dive C, Renehan AG. Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives. Annual Review of Medicine. 2010;61:301–16. pmid:19824817
- 73. Maso LD, Zucchetto A, Vecchia CL, Montella M, Conti E, Canzonieri V, et al. Prostate cancer and body size at different ages: an Italian multicentre case–control study. British Journal of Cancer. 2004;90:2176–80. pmid:15150581
- 74. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK-H, Briganti A, Walz J, et al. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. International Journal of Cancer. 2007;121:791–5. pmid:17455251
- 75. Dimitropoulou P, Martin RM, Turner EL, Lane JA, Gilbert R, Davis M, et al. Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. British Journal of Cancer. 2011;104:875–81. pmid:21266978
- 76. Hack EE, Siemens DR, Groome PA. The relationship between adiposity and gleason score in men with localized prostate cancer. The Prostate. 2010;70:1683–91. pmid:20564314
- 77. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071–8. pmid:15164171
- 78. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132(6):2208–25. pmid:17498513
- 79. Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, Neal DE, et al. Association of diabetes mellitus with prostate cancer: nested case–control study (Prostate testing for cancer and treatment study). International journal of cancer. 2011;128(2):440–6. pmid:20473853